IL-23 inhibitors in psoriasis treatment: Current perspectives and emerging horizons
Meditsinskiy sovet = Medical Council · 31.03.2025 · (2) · 59-64
DOI: 10.21518/ms2025-030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 31.03.2025. Verfasst von О. V. Zhukova und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Interleukin-23 (IL-23) inhibitors have become a crucial tool in the treatment of psoriasis. This group of genetically engineered biological drugs offers promising prospects for achieving long-term remission and improving patients’ quality of life. Modern therapies, such as guselkumab, demonstrate high efficacy in achieving complete skin clearance (PASI 90/100) and maintaining treatment outcomes, even in patients with a long history of the disease or previous failure with TNF or IL-17 inhibitors. Particularly noteworthy are recent studies aimed at confirming the concept of disease modification. According to the latest findings, early intervention using IL-23 inhibitors accelerates remission and increases the frequency of super-response, especially in patients with a short history of severe psoriasis (≤2 years). The concept of disease modification (DM), defined as a sustainable change in the pathophysiology of psoriasis that minimizes the need for ongoing treatment, underscores the importance of IL-23 inhibitors. Key criteria for DM include reducing BSA to
Zitieren
APA
Zhukova, О. V., & Artemyeva, S. I. (2025). IL-23 inhibitors in psoriasis treatment: Current perspectives and emerging horizons. Meditsinskiy sovet = Medical Council, 59-64. https://doi.org/10.21518/ms2025-030
Vancouver
Zhukova ОV, Artemyeva SI. IL-23 inhibitors in psoriasis treatment: Current perspectives and emerging horizons. Meditsinskiy sovet = Medical Council. 2025:59-64. doi:10.21518/ms2025-030
BibTeX
@article{Zhukova2025,
author = {Zhukova, О. V. and Artemyeva, S. I.},
title = {IL-23 inhibitors in psoriasis treatment: Current perspectives and emerging horizons},
journal = {Meditsinskiy sovet = Medical Council},
year = {2025},
number = {2},
pages = {59--64},
doi = {10.21518/ms2025-030}
}
EUVIMED